{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:09:48Z","timestamp":1773410988596,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.det.2011.06.020","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T09:23:52Z","timestamp":1313573032000},"page":"643-647","source":"Crossref","is-referenced-by-count":17,"title":["Management of Epidermolysis Bullosa Acquisita"],"prefix":"10.1016","volume":"29","author":[{"given":"Lizbeth R.A.","family":"Intong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9d\u00e9e F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2011.06.020_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.det.2011.03.017","article-title":"Diagnosis and clinical features of epidermolysis bullosa acquisita","volume":"29","author":"Caux","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2011.06.020_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.0022-202X.2005.23702.x","article-title":"Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita","volume":"124","author":"Woodley","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1346-8138.2009.00799.x","article-title":"Epidermolysis bullosa acquisita: what\u2019s new?","volume":"37","author":"Ishii","year":"2010","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2230.2010.03845.x","article-title":"Clinical and immunopathological evaluation of epidermolysis bullosa acquisita","volume":"36","author":"Delgado","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0190-9622(81)70076-8","article-title":"Epidermolysis bullosa acquisita: a heterogenous disease","volume":"5","author":"Palestine","year":"1981","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0190-9622(84)80459-4","article-title":"Epidermolysis bullosa acquisita\u2014a pemphigoid-like disease","volume":"11","author":"Gammon","year":"1984","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-4632.2009.03886.x","article-title":"Epidermolysis bullosa acquisita: concise review and practical considerations","volume":"48","author":"Lehman","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clindermatol.2010.07.010","article-title":"Autoimmune blistering diseases in the elderly","volume":"29","author":"Parker","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.iac.2007.12.002","article-title":"Ocular manifestations of blistering diseases","volume":"28","author":"Elchalal","year":"2008","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.det.2011.06.020_bib10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/archopht.124.11.1615","article-title":"Chronic cicatrizing conjunctivitis in a patient with epidermolysis bullosa acquisita","volume":"124","author":"Letko","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.det.2011.06.020_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2230.2008.02875.x","article-title":"Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations","volume":"33","author":"Shipman","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib12","article-title":"Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita","volume":"1","author":"Kirtschig","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.det.2011.06.020_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annder.2011.01.019","volume":"138","author":"Le Roux-Villet","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.det.2011.06.020_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14656566.2011.549127","article-title":"Current concepts in the treatment of epidermolysis bullosa acquisita","volume":"12","author":"G\u00fcrcan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.det.2011.06.020_bib15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1067\/mjd.2001.113693","article-title":"Emerging treatment for epidermolysis bullosa acquisita","volume":"44","author":"Engineer","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/00015555-1065","article-title":"Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases","volume":"91","author":"Kim","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2011.06.020_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/0190-9622(91)70107-D","article-title":"Childhood epidermolysis bullosa acquisita","volume":"24","author":"Arpey","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000079608","article-title":"Superpotent topical steroid therapy for epidermolysis bullosa acquisita","volume":"209","author":"Abecassis","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2011.06.020_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2008.12.020","article-title":"A\u00a0case of epidermolysis bullosa acquisita with clinical features of Brunsting-Perry pemphigoid showing an excellent response to colchicine","volume":"61","author":"Tanaka","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0190-9622(96)90013-4","article-title":"Colchicine for epidermolysis bullosa acquisita","volume":"34","author":"Cunningham","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0190-9622(87)80239-6","article-title":"Treatment of epidermolysis bullosa acquisita with cyclosporine","volume":"16","author":"Connolly","year":"1987","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0190-9622(88)70254-6","article-title":"Clearing of epidermolysis bullosa acquisita with cyclosporine","volume":"19","author":"Crow","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jaad.2005.07.009","article-title":"Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent","volume":"54","author":"Tran","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2006.06.016","article-title":"Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2)","volume":"56","author":"Smith","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib25","first-page":"521","article-title":"Intravenous immunoglobulin for treatment of severe acquired bullous epidermolysis refractory to conventional immunosuppressive therapy","volume":"85","author":"Mosquiera","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib26","first-page":"331","article-title":"Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita","volume":"34","author":"Kofler","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib27","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaad.2006.06.029","article-title":"High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases","volume":"56","author":"Segura","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clim.2008.08.003","article-title":"Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita","volume":"129","author":"Tayal","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.det.2011.06.020_bib29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2006.07596.x","article-title":"A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita","volume":"156","author":"Crichlow","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib30","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1111\/j.1365-2230.2009.03608.x","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab","volume":"34","author":"Saha","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archderm.142.2.147","article-title":"Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab","volume":"142","author":"Schmidt","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/archderm.143.2.192","article-title":"Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)","volume":"143","author":"Niedermeier","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaad.2009.09.045","article-title":"Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease","volume":"64","author":"Li","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.annder.2009.02.007","volume":"136","author":"Cavailhes","year":"2009","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.det.2011.06.020_bib35","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/clim.2001.5113","article-title":"Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab","volume":"101","author":"Egan","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.det.2011.06.020_bib37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(86)70103-5","article-title":"Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer","volume":"14","author":"Furue","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2133.1995.tb02680.x","article-title":"Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy","volume":"133","author":"Miller","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.transci.2010.10.006","article-title":"Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy","volume":"43","author":"Sanli","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.det.2011.06.020_bib40","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib41","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaad.2010.06.003","article-title":"Pemphigus: directions for the future","volume":"64","author":"Martin","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2011.06.020_bib42","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863511001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863511001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T12:56:26Z","timestamp":1543582586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863511001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0733863511001288"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2011.06.020","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}